Moderna: Stock to Avoid or Bad News Buy?

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The stock soared more than 700% through 2020 and into the first weeks of 2021, and peak vaccine sales reached more than $18 billion for the 2022 full year. But, as demand for coronavirus vaccines waned during later stages of the pandemic, Moderna's growth didn't last. The company embarked on cost cuts and realigned its pipeline to build out a seasonal vaccines portfolio and focus on big opportunities, such as oncology and rare disease therapeutics.Though Moderna has made progress along this new path, it's also reached some bumps. And the latest happened just this week, when the U.S. Food and Drug Administration said it wouldn't review Moderna's flu vaccine application. The flu candidate, mRNA-1010, represents an integral part of Moderna's seasonal vaccine portfolio. Moderna stock fell more than 3% in one trading session following the news. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool